RGX-314 is targeted for treating wet age-related macular degeneration, a leading cause of total and partial vision loss. Regenxbio started enrolling …

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *